胰腺癌免疫疗法的未来以及迄今为止的试验、磨难与成功。
Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
作者信息
Wong Winston, Alouani Emily, Wei Alexander, Ryu Yun Kyoung, Chabot John A, Manji Gulam A
机构信息
Division of Hematology and Oncology, Columbia University Irving Medical Center, and New York Presbyterian Hospital, New York, NY.
Division of Hematology and Oncology, Columbia University Irving Medical Center, and New York Presbyterian Hospital, New York, NY.
出版信息
Semin Oncol. 2021 Feb;48(1):57-68. doi: 10.1053/j.seminoncol.2021.02.007. Epub 2021 Apr 17.
Pancreas ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rate of 10%. Currently, chemotherapy remains the standard of care for systemic treatment. Immunotherapy with checkpoint inhibitors unfortunately has not been found to be effective in the treatment of PDAC to date, likely due to the highly desmoplastic and immunosuppressive tumor microenvironment (TME). Treatment targeting pathways against the immunosuppressive mechanisms of PDAC are of mounting interest to improve outcomes in PDAC. In this review, we discuss prior efforts and the current state of immunotherapy in PDAC. We will also review the emerging targets and treatments with significant clinical potential for the treatment of PDAC such as: CD40 pathway, the adenosine pathway, the CXCR4/CXCL12 axis, the CCR2/CCL2 axis, IDO pathway, and others.
胰腺导管腺癌（PDAC）的预后很差，5年生存率为10%。目前，化疗仍然是全身治疗的标准疗法。不幸的是，迄今为止，检查点抑制剂免疫疗法在PDAC治疗中尚未发现有效，这可能是由于其高度促结缔组织增生和免疫抑制的肿瘤微环境（TME）。针对PDAC免疫抑制机制的靶向治疗途径越来越受到关注，以改善PDAC的治疗效果。在本综述中，我们讨论了PDAC免疫治疗的前期研究和现状。我们还将综述具有显著临床潜力的新兴靶点和治疗方法，用于治疗PDAC，例如：CD40途径、腺苷途径、CXCR4/CXCL12轴、CCR2/CCL2轴、IDO途径等。
Zotero 插件